Slide 1: ACRUX FY23 results
ACRUX FY23 results Acrux (ASX:ACR) is a specialty pharmaceutical company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. August 2023 1
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of p
Slide 3: FY23 Key Milestones
FY23 Key Milestones Launched • Lidocaine 2.5% and Prilocaine 2.5%, Cream a generic of topical anaesthetic Emla® was launched by our partner in December 2022. Accepted for review • Acyclovir Cream, 5% a generic treatment for cold sores was accepted for review by FDA in August 2022 Monetised • In Janu
Slide 4: Acrux portfolio
Acrux portfolio • The Company now has: • 16 products in its portfolio • 6 approved products (4 commercialised, 2 pending commercialisation) • 3 products currently being reviewed by the FDA • Acrux intends to maintain a pipeline of 10–12 products • Progression of Acrux’s portfolio of products FY20 FY
Slide 5: Product Development Pipeline (August 2023)
Product Development Pipeline (August 2023) 5
Slide 6: Acrux is focussed on an underserved market segment
Acrux is focussed on an underserved market segment Source: 1. US market by dosage form, IQVIA Q3, 2020 MAT, US$ market sales 2. Market size for topically applied drugs IQVIA Q3, 2020 MAT, USS market sales 6
Slide 7: Key Objectives FY24
Key Objectives FY24 Launch Dapsone 5%, Gel Continued revenue growth from Prilocaine and Lidocaine 2.5%, Cream Obtain FDA approval and launch products currently under FDA review Advance additional pipeline products 7
Slide 8: FY23 Financials
FY23 Financials ACRUX
Slide 9: Revenue from product licensing
Revenue from product licensing FY23 total Revenue from product licensing was $8.429million including: $000 • $6.337million from the buy out of future Lenzetto® Royalties transacted in January 2023 • A significant increase from $1.179million for FY22 • Portfolio Profit Share / Royalty grew by $0.845m
Slide 10: Profitability and Cash Generation
Profitability and Cash Generation $000 2022 2023 Client revenue 1,719 8,429 Other Revenue 3,383 3,499 Total Revenue 5,103 11,928 $000 COGS - 558 External R&D 6,371 3,813 OPEX 8,313 7,448 Total Cash Expenses 14,684 11,818 Impairment - 321 Profit Before Tax (9,582) (212) Total Revenue growth, which in
Slide 11: Acrux investment opportunity
Acrux investment opportunity • Track record of developing and commercialising products: • Extensive pipeline of products under development with 3 products currently under evaluation by the FDA • Lidocaine 2.5% and Prilocaine 2.5% cream successfully launched in December 2022 • Received FDA approval o
Slide 12: Thank You
Thank You 12